Mean change from baseline to 52 weeks was similar for ranibizumab 0.5 q4 and intravitreal aflibercept 2q8 across all 12 subscales , with the greatest improvements noted for mental health and general vision ( 9.0-11 .6 points , both treatments , both studies ) .